Skip to main content
    T

    Talphera Inc. (TLPH)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $1.06
    -0.01 (-0.93%)

    Market Cap: $55.02M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    74%(29/39)
    Avg Surprise
    -13.56%
    Streak
    10 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.06
    Range$-0.06 - $-0.05
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.07+15.4%
    60d ago$-0.07+17.5%
    30d ago$-0.07+17.5%
    7d ago$-0.07+17.5%
    Current$-0.06
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.01
    Range$-0.01 - $0.00
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.01---
    Sep 26EST
    		-$-0.06---
    Jun 26
    Reported Aug 12
    		$-0.06$-0.07+14.29%Beat+40.0%
    Mar 26
    Reported May 13
    		$-0.05$-0.08+37.50%Beat+54.5%
    Dec 25
    Reported Mar 23
    		$-0.06$-0.07+20.00%Beat+14.3%
    Sep 25
    Reported Nov 12
    		$-0.11$-0.11+0.00%Beat+15.4%
    Jun 25
    Reported Aug 14
    		$-0.10$-0.11+9.09%Beat+33.3%
    Mar 25
    Reported May 13
    		$-0.11$-0.14+21.43%Beat+35.3%
    Dec 24
    Reported Mar 31
    		$-0.07N/A+56.25%Beat+72.0%
    Sep 24
    Reported Nov 13
    		$-0.13$-0.20+35.00%Beat-62.5%
    Jun 24
    Reported Aug 14
    		$-0.15$-0.20+25.00%Beat+63.4%
    Mar 24
    Reported May 14
    		$-0.17$-0.21+19.05%Beat+77.3%
    Dec 23
    Reported Mar 6
    		$-0.25$-0.20-25.00%Miss+75.0%
    Sep 23
    Reported Dec 6
    		$-0.08N/A+69.23%Beat+91.5%
    Jun 23
    Reported Aug 10
    		$-0.41$-0.53+22.64%Beat+64.3%
    Mar 23
    Reported May 10
    		$-0.75$-0.51-47.06%Miss+37.5%
    Dec 22
    Reported Mar 30
    		$-1.00$-0.10-900.00%Miss-1566.7%
    Sep 22
    Reported Nov 14
    		$-0.94$-1.20+21.67%Beat+32.9%
    Jun 22
    Reported Aug 11
    		$-1.15$-1.20+4.17%Beat+28.1%
    Mar 22
    Reported Jun 29
    		$-1.20$-1.20+0.00%Beat+25.0%
    Dec 21
    Reported Mar 30
    		$-0.06$-0.07+7.69%Beat+40.0%
    Sep 21
    Reported Nov 15
    		$-1.40$-1.40+0.00%Beat+30.0%
    Jun 21
    Reported Aug 16
    		$-1.60$-1.60+0.00%Beat+0.0%
    Mar 21
    Reported Jun 29
    		$-1.60$-1.70+5.88%Beat-700.0%
    Dec 20
    Reported Mar 30
    		$-0.10$-0.10+3.19%Beat+97.2%
    Sep 20
    Reported Nov 5
    		$-2.00$-1.80-11.11%Miss+37.5%
    Jun 20
    Reported Aug 10
    		$-1.60$-2.40+33.33%Beat+50.0%
    Mar 20
    Reported Jun 29
    		$-0.20$-0.17-17.65%Miss+94.1%
    Dec 19
    Reported Mar 30
    		$-3.60$-3.67+1.91%Beat-1900.0%
    Sep 19
    Reported Nov 7
    		$-3.20$-4.20+23.81%Beat+23.8%
    Jun 19
    Reported Aug 5
    		$-3.20$-4.52+29.20%Beat+20.0%
    Mar 19
    Reported Jun 29
    		$-3.40$-4.36+22.02%Beat+26.1%
    Dec 18
    Reported Mar 30
    		$-0.18$-0.20+10.00%Beat+10.0%
    Sep 18
    Reported Nov 2
    		$-4.20$-4.06-3.45%Miss+25.0%
    Jun 18
    Reported Aug 2
    		$-4.00$-3.80-5.26%Miss+31.0%
    Mar 18
    Reported Jun 29
    		$-4.60$-5.00+8.00%Beat+32.4%
    Dec 17
    Reported Mar 30
    		$-0.20$-0.20+0.00%Beat+4.8%
    Sep 17
    Reported Nov 9
    		$-5.60$-5.37-4.28%Miss-
    Jun 17
    Reported Aug 1
    		$-5.80$-5.64-2.84%Miss-
    Mar 17
    Reported Jun 29
    		$-6.80$-5.44-25.00%Miss-
    Dec 16
    Reported Mar 30
    		$-0.21$-0.24+12.50%Beat-

    Key Metrics

    Valuation
    P/E Ratio-3.79EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-1000000.00%
    ROE-143.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio4.29xQuick Ratio4.29x
    Trading Statistics
    Beta0.68Avg Volume150.21K
    52-Week High$1.5752-Week Low$0.69

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.09
    SMA 20$1.13
    SMA 50$1.20
    SMA 200$1.01
    EMA 10$1.09
    EMA 20$1.12
    EMA 50$1.16
    EMA 200$1.05

    MACD

    Line: -0.04Signal: -0.03Hist: -0.01

    ADX

    ADX: 17.6+DI: 14.7-DI: 30.0

    Aroon & PSAR

    Aroon Up12.0
    Aroon Down84.0
    PSAR$1.20

    Bollinger Bands

    Upper Band$1.22
    Lower Band$1.04
    %B Position1632%(Upper)
    Band Width0.11

    RSI (14-Day)

    Neutral
    33.8

    Momentum Oscillators

    Stoch %K22.2
    Stoch %D25.3
    Williams %R-83.3
    ROC (10d)-8.6%
    Momentum-0.10
    CCI (20d)-120.8
    MFI (14d)44.4

    Volatility Measures

    ATR (14d)$0.04(4.0%)
    StdDev (20d)0.05
    Hist Vol33.0%(Moderate)

    Volume Flow

    VWAP$1.06
    OBV126.7M
    AD Line-42.9M
    CMF (20d)-0.059

    Volume Metrics

    Avg Vol (20d)145.6K
    Vol Ratio0.3x(Low)
    VWMA (20d)$1.13

    Pivot Points

    R3$1.11
    R2$1.09
    R1$1.08
    Pivot Point$1.07
    S1$1.06
    S2$1.04
    S3$1.03

    Advanced Oscillators

    TSI-26.61
    Ultimate Osc34.2
    KST-84.03

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$1,000$0$27,000$6.68M$0$0$0$281,000$117,000
    Cost of Revenue$0$0N/A$0$0$0$1.32M$0$0$0$1.77M$0
    Gross Profit$0$0N/A$1,000$0$27,000$-1,323,000$0$0$0$281,000$117,000
    Operating Expenses$3.92M$3.95M$3.45M$3.42M$3.69M$2.94M$3.00M$3.75M$4.27M$4.24M$4.56M$3.43M
    R&D$1.69M$1.65M$1.56M$1.80M$1.50M$1.17M$1.32M$2.05M$1.91M$1.43M$1.77M$1.18M
    SG&A$2.23M$2.30M$1.89M$1.62M$2.19M$1.77M$1.67M$1.70M$2.36M$2.80M$2.79M$2.25M
    Operating Income$-3,924,000$-3,948,000$-3,453,000$-3,422,000$-3,693,000$-2,916,000$-2,996,000$-3,749,000$-4,270,000$-4,237,000$-4,283,000$-3,309,000
    Interest Income$172,000$169,000$203,000$81,000$83,000$69,000$103,000$155,000$201,000$220,000$171,000$187,000
    Interest Expense$388,000$0$319,000$1.01M$0$0$0$0$213,000$181,000$227,000$0
    Income Before Tax$-4,312,000$-2,556,000$-3,772,000$-4,436,000$-3,489,000$-2,666,000$-1,870,000$-3,353,000$-3,827,000$-3,954,000$-4,510,000$-1,416,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$2,000
    Net Income$-4,312,000$-2,556,000$-3,772,000$-4,436,000$-3,489,000$-2,593,000$-1,870,000$-3,353,000$-3,827,000$-3,954,000$-4,517,000$-1,357,000
    EBITDA$-4,637,000$-2,809,000$-4,100,000$-4,534,000$-3,572,000$-2,735,000$-1,973,000$-3,508,000$-3,864,000$-4,065,000$-4,690,000$-1,603,000
    EBIT$-4,484,000$-2,725,000$-3,975,000$-4,517,000$-3,572,000$-2,735,000$-1,973,000$-3,508,000$-3,815,000$-3,993,000$-4,681,000$-1,603,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TLPH

    News

    Talphera Inc. R (R5XA.MU) Q1 FY2026 earnings call transcript

    Talphera Inc. announced that enrollment for its NEPHRO study has progressed beyond 50%, with top-line data expected in the second half of 2026. The company's Q1 2026 cash operating expenses increased to $3.9 million due...

    Yahoo Finance•10/14/26•Neutral

    Talphera at H.C. Wainwright conference: nafamostat path gains traction By Investing.com

    Talphera presented at the H.C. Wainwright 28th Annual Global Investment Conference, detailing advancements in its NEPHRO pivotal study for nafamostat mesylate...

    Investing.com Canada•9/14/26•Bullish

    Conferencia de resultados del T2 de 2026 de Talphera (TLPH): la inscripción en NEPHRO CRRT alcanza el 75 %

    Talphera (TLPH) announced that enrollment in its NEPHRO CRRT study has reached 75%, with completion expected by late 2026 and a PMA application submission targeted for the first half of 2027. The company's cash balance...

    TradingKey•8/18/26•Bullish

    HC Wainwright Has Negative View of Talphera FY2029 Earnings

    HC Wainwright has lowered its FY2029 earnings per share estimate for Talphera (NASDAQ:TLPH) to $0.12 from $0.13...

    MarketBeat•8/14/26•Somewhat-Bearish

    Talphera (TLPH) Q2 2026 Earnings Call: NEPHRO CRRT Enrollment Reaches 75%

    Talphera announced that its NEPHRO CRRT study enrollment has reached 75%, with all clinical sites activated, keeping it on track for completion later in 2026. The company expects top-line data four to five weeks after...

    TradingKey•8/14/26•Bullish

    TLPH Valuation and Fair Value

    P/E
    -3.8x
    Forward P/E
    1.0x
    P/B
    5.6x
    See GNG's fair value

    TLPH Profitability: Margins, ROIC and FCF

    Operating margin
    -1000000.0%
    Net margin
    0.0%
    ROE
    -143.4%
    FCF margin
    -1227000.0%

    TLPH Competitors

    CompanyTicker
    RenovoRx IncRNXT
    Pliant Therapeutics IncPLRX
    Pheton Holdings Ltd Class A Ordinary SharesPTHL
    Gossamer Bio IncGOSS
    Connect Biopharma Holdings LtdCNTB
    Fractyl Health, Inc. Common StockGUTS
    Gain Therapeutics IncGANX
    Kezar Life Sciences IncKZR

    Sector: Healthcare

    TLPH Bull Case vs Bear Case

    Bull case

    • TLPH beat EPS estimates in 87.5% of its last 8 reported quarters.

    TLPH Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    24.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.06
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About TLPH

    Does TLPH pay dividends?

    Talphera Inc. (TLPH) does not currently pay a regular dividend.

    What is TLPH's market cap?

    Talphera Inc. (TLPH) has a market capitalization of $55.02M with a current stock price of $1.06.

    Related stocks

    Sector: Healthcare

    All stocks starting with T

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In